Brian E. Schwartz
Affiliations: | DFCI, Boston, MA, United States |
Area:
transcriptionGoogle:
"Brian Schwartz"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Leoni C, Gullo G, Resta N, et al. (2019) First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma. American Journal of Medical Genetics. Part A |
| Busset MDD, El-Rayes BF, Harris WP, et al. (2019) Derazantinib (DZB) provides antitumor efficacy regardless of line of therapy in patients (pts) with FGFR2-fusion positive advanced intrahepatic cholangiocarcinoma (iCCA). Journal of Clinical Oncology. 37 |
| Woyach J, Stephens DM, Flinn IW, et al. (2019) Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies Blood. 134: 4298-4298 |
| Yu Y, Harring A, Volckova E, et al. (2019) Abstract C076: In vitro and in vivo combination of ARQ 751 with PARP inhibitors, CDK4/6 inhibitors, Fulvestrant and Paclitaxel Molecular Cancer Therapeutics. 18 |
| Pant S, Lamar M, Kazakin J, et al. (2019) Abstract A034: The use of biomarkers and ctDNA in a phase 1 trial of ARQ 751 Molecular Cancer Therapeutics. 18 |
| Beg M, Boothman D, Khosama L, et al. (2019) A phase I/Ib, multi-center trial of ARQ-761 (Beta-Lapachone) with gemcitabine/nab-paclitaxel in patients with advanced pancreatic cancer Annals of Oncology. 30: v271 |
| Buttigliero C, Shepherd FA, Barlesi F, et al. (2018) Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. The Oncologist |
| Reiff SD, Mantel R, Smith LL, et al. (2018) The BTK Inhibitor ARQ 531 Targets Ibrutinib Resistant CLL and Richter's Transformation. Cancer Discovery |
| Rimassa L, Assenat E, Peck-Radosavljevic M, et al. (2018) Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. The Lancet. Oncology |
| Ranieri C, Di Tommaso S, Loconte DC, et al. (2018) In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS). Neurogenetics |